Aims and objectives of this presentation

There is an increasing interest in the role of truncated androgen receptors in prostate cancer. These potentially very important biomarkers have been identified in several publications, however scientific consensus has to be reached. In addition, controversies on activated transcription factors as biomarkers will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

16:08 - 16:18

Prostate cancer biomarkers: What's new?
H.G. Lilja, New York (US)

*1064

Delivery of precision medicine in advanced prostate cancer using circulating tumour cells
By: Rhee H.¹, Gunter J.², Javanovic L.³, Williams E.², Hollier B.², Nelson C.², Vela I.³
Institutes: Princess Alexandra Hospital/Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ²Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia

*1065

Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer
By: Josefsson A., Damber J-E., Welén K.
Institutes: Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Dept. of Urology, Gothenburg, Sweden

*1067

SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer
By: Wadhwa K.¹, Bon H.², Holmes K.³, Warren A.⁴, Whittaker H.⁵, Kay J.⁵, Fryer L.², Neal D.², Gnanapragasam V.¹, Carroll J.³
Institutes: ¹Academic Urology Group, Dept. of Urology, Cambridge, United Kingdom, ²Neal Laboratory, Dept. of Uro-Oncology, Cambridge, United Kingdom, ³Carroll Laboratory, Cambridge Institute CRUK, Cambridge, United Kingdom, ⁴Addenbrooke’s Trust University of Cambridge, Dept. of Pathology, Cambridge, United Kingdom, ⁵Biomarker Group, Cambridge Institute CRUK, Cambridge, United Kingdom

*1068

Expression of pSTAT3 in prostate cancer metastases from different organs
By: Don-Doncow N.¹, Marginean F.¹, Morrisey C.², Hellsten R.¹, Bjartell A.¹
Institutes: ¹Lund University Hospital, Dept. of Translational Medicine Malmö, Malmö, Sweden, ²University of Washington, Dept. of Urology, Seattle, United States of America

*1069

Intratumoral heterogeneity of mTOR-pathway parameters in prostate cancer
By: Schanz M.¹, Hennenlotter J.¹, Dlugosch J.¹, Kuehs U.¹, Dettmer M.², Schilling D.³, Schwentner C.¹, Stenzl A., Todenhöfer T.
Institutes: ¹Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ²Universitätsklinik Bern, Dept. of Pathology, Berne, Germany, ³Isar Klinikum, Dept. of Urology, Munich, Germany
Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients
By: Teishima J.1, Nagamatsu H.1, Shoji K.1, Yamanaka R.1, Kobatake K.1, Kitano H.1, Goto K.1, Shinmei S.1, Hayashi T.1, Oue N.2, Yasui W.2, Matsubara A.1
Institutes: Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Urology, Hiroshima, Japan, Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan

The role of genomic classifier to assess post-operative metastatic risk for prostate cancer patients based on final pathology characteristics
By: Woodlief T.L., Rocco B., Ramharack R., Gnapathi H., Ogaya G., Mouravieve V., Patel V.
Institutes: Florida Hospital, Global Robotics Institute, Celebration, United States of America

A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer
By: Heck M.1, Thalgott M.1, Schmid S.1, Oh W.2, Gong Y.2, Wang L.2, Zhu J.3, Seitz A-K.1, Porst D.1, Höppner M.1, Retz M.1, Gschwend J.1, Nawroth R.1
Institutes: Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Hematology/Oncology, New York, United States of America, Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Genetic and Genomic Sciences, New York, United States of America

Prostate cancer copy number score predicts metastatic disease
By: Van Den Broeck T.1, Gevaert T.1, Prekovic S.2, Smeets E.2, Helsen C.2, Lambrechts D.3, Boeckx B.3, Joniau S.1, Claessens F.2
Institutes: University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, KU Leuven, Laboratory For Translational Genetics, Vesalius Research Center, VIB, Leuven, Belgium

Microseminoprotein-beta expression in different stages of prostate cancer
Institutes: Tampere University Hospital, Dept. of Surgery, Tampere, Finland, University of Tampere, BioMediTech, Tampere, Finland, Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, University of Turku, BioMediTech, Tampere, Finland

PD-L1 expression in castration-resistant prostate cancer (CRPC)
By: Frankhauser C.1, Schüffler P.2, Gillessen S.3, Omlin A.3, Hermanns T.1, Poyet C.4, Sulser T.1, Moch H.4, Wild P. J.4
Institutes: University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, Memorial Sloan Kettering Cancer Center, The Thomas Fuchs Lab, New York, United States of America, Canton Hospital, St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland, University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland